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ABSTRACT
Red blood cell distribution width (RDW) is a quantitative measure of the
variability in size of circulating erythrocytes. It was recently reported that RDW is a
prognostic factor for infection diseases, cardiovascular and pulmonary diseases, as
well as some neoplasms. Moreover, RDW is remarkably strong predictor of longevity,
including all causes of death, for adults aged 45 years and older. To explain this
occurrence it was proposed that persistent IGFs/mTOR signaling is one of the factors
that play a role in affecting the RDW and mortality.
The above observations induced us to analyze the prognostic role of RDW in
chronic lymphocytic leukemia (CLL) being the most frequent type of adult leukemia in
Western countries. The obtained results have shown that RDW may be considered as a
potential CLL prognostic marker. Elevated RDW level at the moment of diagnosis was
associated with advanced disease and presence of other poor prognostic factors. It is
also connected with overall survival indicating shorter time in patients with elevated
RDW. It is possible that the presently observed correlation between mortality and
RDW of the CLL patients is affected by their metabolic (IGF-1/mTOR driven)- rather
than chronological- aging. The patients with high level of RDW are expected to have
an increased persistent level of IGF-1/mTOR signaling. Within the framework of
personalized therapy, these CLL patients therefore would be expected to be more
sensitive to the treatment with mTOR inhibitors.

INTRODUCTION

Clinical course and prognosis of CLL are reported as
extremely variable. Some persons with benign course never
require therapy and die because of other than leukemic ones
causes. In others the disease is aggressive and treatment
is started soon after diagnosis. Many prognostic factors
are used to predict clinical outcome of CLL patients. The
clinically important ones are connected with the biology of
the disease -the mutation status of the variable segment of
immunoglobulin heavy chain genes (IgVH)), ZAP-70 and
CD38 expression as indicators for IgVH mutations, as well
as gene and genomic abnormalities [7, 8, 9, 10].
Red blood cell distribution width (RDW) is a
quantitative expression of the size heterogeneity of
peripheral blood erythrocytes and is being usually
automatically reported by laboratory blood analyzers in
a complete blood cell count panels. RDW is presented
as coefficient of variation (cv) of the mean value of

Chronic lymphocytic leukemia (CLL) is the most
frequently diagnosed leukemia of older patients in Western
countries. The disease is characterized by the accumulation
of leukemic CD19+/CD5+/CD23+ B cells in the blood,
bone marrow, lymph nodes and spleen [1, 2, 3]. Lots of
mechanisms involved in leukemic transformation are
reported. The deletion of specific micro-RNA genes leads
to the resistance of B lymphocytes towards apoptosis [1, 4].
The B cell receptor (BCR) signaling plays an important
pathogenic role because of BCR-dependent survival of
leukemic lymphocytes [5]. Additionally, the accessory cells
of microenvironment can promote leukemic cell growth.
BCR and chemokine receptors were reported to allow
lymphocytes to be localized in lymphoid tissues and to form
the CLL microenvironment [6].
www.impactjournals.com/oncotarget

32846

Oncotarget

erythrocytes volume (Coulter volume). Recently, the role of
RDW as a prognostic marker for infections, such as severe
sepsis, pneumonia, infections caused by gram-negative
bacteria and necrotizing fasciitis was described [11, 12,
13, 14]. An elevated RDW unrelated of hemoglobin level,
is connected with severe morbidity and mortality in the
case of cardiovascular diseases, in kidney and pulmonary
disorders [15, 16, 17, 18, 19]. RDW as a prognostic factor
in hematological diseases was reported in patients with
multiple myeloma [20]. Furthermore, RDW seems to be
strong predictor of longevity, including all causes of death,
with no apparent relationship to a particular disease, for
people of age 45 and older [21].
The presented article aimed to analyze the possible
role of RDW as a marker of prognosis in patients with CLL.
Such a role of this parameter was expected because of the
impairment of immunity in CLL patients and the fact that
RDW is believed to reflect the general state of the patients
and comorbidities related to their age, cardiovascular
abnormalities or other infections.

The patients were divided into two groups according
to ZAP-70 and CD38 expression into positive group with
ZAP-70 > 20% and CD38 > 20%, respectively and the
negative group with ZAP-70 < 20% and CD38 < 20%,
respectively. According to cytogenetic abnormalities the
group of high-cytogenetic risk (del17p and del11q) and
standard-cytogenetic risk group (trisomy of chromosome 12,
del13q, no cytogenetic abnormalities) were distinguished.
The RDW values were compared in the above groups. RDW
was statistically significant higher in ZAP-70 positive and
CD38 positive patients in comparison to ZAP-70 negative
and CD38 negative subjects, respectively. In reference to
cytogenetic changes, the difference were not statistically
significant, however RDW was higher in high-cytogenetic
risk group than in standard-cytogenetic risk one (Figure 2).

RDW assessment in regard to clinical outcomes
The clinical outcome data were analyzed in the
group of patients who had to start the treatment (38 out of
66 patients). The difference in time to treatment between
low -RDW group and high-RDW group was observed,
however it was not statistically significant. The median
time to treatment in low-RDW group was not reached
(58% probability to survive 5 years without therapy) and
it was 2 months in high-RDW group (p > 0.05). There
were no statistically significant differences in response
to chemotherapy in the group of analyzed patients. The
median overall survival time in low-RDW group was not
reached (the probability to survive 5 years was 77%), while
in high-RDW patients it was 52 months. This difference
was at the border of statistical significance (p = 0.05). The
Kaplan–Meier estimates of time to treatment and overall
survival time are illustrated in Figure 3. In multivariate Cox
proportional hazard regression analysis of RDW plus other
prognostic factors: CD38 expression, ZAP-70 expression
and group of cytogenetic risk (not simple cytogenetic
abnormalities), the RDW level and ZAP-70 expression were
found to be the independent predictors of shorter survival
(p = 0.04 and p = 0.03, respectively).
In the group of treated patients we analyzed RDW
values longitudinally in particular subjects in different
points such as the moment of diagnosis, the disease
progression and the end of chemotherapy. There was no
significant differences in RDW as the disease progress.
In most of cases RDW remained in the same group of
stratification (low-RDW or high-RDW). Thus, RDW seems
to be stable, not time-dependent prognostic marker.

RESULTS
Patients characteristics
A total number of 66 previously untreated persons
with CLL diagnosis were analyzed. The median age was 63
years, and 60% were males. Clinical characteristics of entire
group of patients enrolled into the study is shown in Table 1.
The median of pre-treatment RDW level was 13.5%, and the
values ranged from 8.7 to 22.6%, while the normal ranges
are established between 11.5% and 14.5%. The 14.5% cutoff was used for analysis as first selection. Additionally, we
performed the receiver operating characteristic (ROC) curve
assessment of RDW for ZAP-70 positive/negative, CD38
positive/negative, clinical classification early/advanced and
cytogenetic risk standard/high, respectively, to find another
significant cut-off points for RDW values. The estimated
RDW cut-off point for ZAP-70 was 12.7%, for CD38–
13.7%, for clinical stadium was 14% and for cytogenetic risk
groups–13.5%. However, the survival analysis has shown no
significant differences in groups stratified according to these
cut-offs. Thus, the selection of a 14.5% cut off for RDW
positivity was chosen for final analysis. The analyzed subjects
were classified as high-RDW (> 14.5%) and low-RDW
(< 14.5). Table 2 presents clinical and laboratory parameters
of persons stratified according to the RDW. High-RDW
group included older persons comparing to low-RDW group,
however the differences were not statistically significant.
There were no statistically significant differences between
the analyzed groups regarding white blood cell count and
lymphocytosis, platelet count, lactate dehydrogenase level,
β2-microglobulin level, presence of constitutive symptoms,
lymphadenopathy or splenomegaly. Patients of high-RDW
group were at more advanced stages when compared to
low-RDW group (Figure 1).
www.impactjournals.com/oncotarget

DISCUSSION
An elevated RDW has been found as a poor
prognostic factor in several diseases. Specifically, it is
associated with high rate of morbidity and mortality in
the case of patients with chronic heart failure [22, 23, 24].
Likewise, it is a marker of poor prognosis for patients with
32847
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Table 1: Clinical characteristics of analyzed CLL patients
Characteristics

Median (range)

Sex
Female
Male
Age
Rai stadium
0
I
II
III
IV
CD38 expression
Negative
Positive
ZAP-70 expression
Negative
Positive
Cytogenetics
Low-risk
High-risk
First-line therapy
Fludarabine-based regimens
Chlorambucil+/−Prednisone
Bendamustine

Number of patients/percentage
30
36

63 (38–85)
31%
17%
30%
8%
14%
56%
44%
68%
32%
60%
40%
30
7
1

Table 2: Clinical parameters of analyzed CLL patients of Low-RDW (< 14.5%) and High-RDW
(> 14.5%) groups
Low - RDW Group

High -RDW Group

p

59

63

NS

Lymphocytosis (109/L)

48 ± 43.5

75.7 + 60.3

NS

Hemoglobin (g%)

12.8 ± 1,7

11.4 ± 1.8

p < 0.05

Platelets (109/L)

157 ± 75,2

140 ± 70.6

NS

LDH (IU/L)

370 ± 126

408 ± 145

NS

β2-microglobulin (mg/dl)

2.34 ± 0.7

5.44 ± 2.7

NS

Age (median)

Statistical significance is indicated (p values); NS – not significant.
infectious diseases [25, 26]. However, there are relatively
few reports focusing on RDW in the area of oncology. It is
known that increase in RDW level indicates the presence
of severe systemic inflammatory state that can worsen
course of neoplastic diseases. RDW level can be influenced
by anemia, which may worsen the course of neoplastic
diseases as well. RDW appears to reflect the general
condition of the patient, including such comorbidities as
age, cardiovascular diseases and inflammation. It was
reported that RDW was higher in women with aggressive
breast cancer and is correlated with shorter survival in
persons with lung cancer [27, 28, 29].
www.impactjournals.com/oncotarget

In the field of hematology the article by Lee et al.
[20] focused on assessment of RDW in patients with
symptomatic multiple myeloma. The observation that RDW
level higher than normal at the moment of diagnosis was in
correlation with more advanced disorder and poor prognosis
prompted the authors to suggest that it could provide a
novel and directly available predictor of severity of the
disease. In fact, RDW may reflect both the inflammatory
status as well as the patient’s global condition [20].
The above observations induced us to analyze the
prognostic role of RDW in CLL. The obtained results
have shown that indeed RDW may be considered a
32848
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Figure 1: Clinical stadium according to Rai classification [30] of the analyzed CLL patients in High-RDW group
(RDW > 14.5 %) and Low-RDW group (RDW < 14.5%).

Figure 2: RDW values in CLL risk groups. RDW values in ZAP-70 negative (ZAP-70-) and ZAP-70 positive (ZAP–70+) CLL
patients (A). RDW values of CLL patients in CD38 negative (CD38−) and CD38 positive (CD38+) group (B). RDW values of analyzed
patients in the standard-risk cytogenetic group (del13q14.3, trisomy 12, or no changes detected) and in the high-risk cytogenetic group
(17p13.1 or 11q22.3) (C). All graphs show mean ± standard deviation. NS not statistically significant.
www.impactjournals.com/oncotarget
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prospective prognostic biomarker in this disease. The
present data demonstrate that RDW is in correlation with
other prognostic factors such as clinical stadium of the
disease, expression of ZAP-70 and CD38. Anemia can
be a symptom of CLL showing the most advanced stage
of disease. In the presented study we have pointed that
hemoglobin level is in correlation with RDW, but other
CLL parameters such as ZAP-70 and CD38 expression
have also changed according to RDW stratification It
should be noted that anemia in neoplastic diseases like
CLL does not simply reflect a decrease in peripheral
blood erythrocytes number but may be a parameter of
inflammation status as well, being associated with impaired
iron release from reticuloendothelial macrophages [20].
Clinical stadium of the disease for many years belongs
to the most important prognostic factors in CLL. Nowadays,
two staging methods - the Rai [30] and the Binet system

[31] co-exist and are widely used in clinical practice. Early
stage 0 disease according to Rai classification describes
patients with lymphocytosis detected in the peripheral
blood and bone marrow. Patients with lymphocytosis and
enlarged lymph nodes are classified at stadium I and those
with splenomegaly at stadium II. High risk disease includes
patients with leukemia-related anemia or thrombocytopenia
(stage III and IV, respectively) [30, 32]. The Binet staging
system is based on the number of involved areas of lymph
nodes or organomegaly and on whether there is anemia
or thrombocytopenia [31, 32]. In general practice, newly
diagnosed patients with asymptomatic early-stage disease
should be observed without treatment. The patients at
intermediate and high risk usually have to start treatment,
however some of them can be observed without therapy
until disease progression [22, 32]. Among the biological
CLL prognostic markers the IgVH mutation status or its

Figure 3: Time to treatment (A) and total survival time (B) demonstrated by Kaplan-Meier curves. The patients were
stratified according to RDW level (Low-RDW group versus High-RDW group). Statistical significance is indicated.
www.impactjournals.com/oncotarget
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surrogate markers (ZAP-70 and CD38 expression) as well
as genomic aberrations may identify the subjects with
more aggressive leukemia and poor prognosis [7, 33]. The
correlations between RDW level and some prognostic
markers of CLL detected in our analysis may indicate the
role of RDW assessment in prognosis of CLL patients.
Further analysis performed in our study was focused
on association between RDW level and clinical outcomes.
We detected no differences between the time of the initiating
of the therapy as far as RDW level was concerned, however
the differences in overall survival time were significant. As
mentioned, strong association between RDW and longevity
has been shown for subjects 45 years and older [21]. This
association remains strong after discounting all types of red
blood cell diseases [21]. To explain this occurrence it was
proposed that persistent signaling along the IGFs/mTOR
pathway is one of the key factors that play a role in affecting
the RDW and mortality [34–36]. Specifically, there are the
data that IGF-1/mTOR signaling enhances erythropoiesis
by activation of erythropoietin [36, 37] and affects the final
steps of erythroid lineage maturation [38]. The IGFs/mTOR
also strikingly influences the cell size as shown for 32Doriginated myeloid cells that are 50% smaller while having
deleted IGF-1 receptor [39]. It may be possible therefore
that persistent activation of erythropoiesis through IGF-1/
mTOR results in heterogeneity of red cell sizes due to their
higher turnover rates. On the other hand the elevated level
of GH/IF-1/mTOR signaling is considered to be the primary
cause of aging and age-associated mortality [39, 40]. Given
the above it may be expected that RDW may be a useful
marker of the constitutive level of IGF-1 signaling, the
critical factor accountable for metabolic aging and longevity
[21]. It is possible, therefore, that the presently observed
correlation between mortality and RDW of the CLL patients
is affected by their metabolically driven (growth factor IGF-1/mTOR)- rather than chronological- aging.
Attempts have been recently made to apply mTOR
inhibitors in treatment of leukemia, including CLL [41,
42, 43]. Along the rationale presented above the patients
with high level of RDW are expected to have an increased
persistent level of IGF-1/mTOR signaling. Within the
framework of personalized therapy, these CLL patients
therefore would be expected to be more sensitive to the
treatment with mTOR inhibitors.
In conclusion, the presented study underscores
the potential role of RDW as a prognostic factor in CLL.
Elevated RDW level at diagnosis was associated with
advanced disease and the presence of other poor prognostic
factors. It was also connected with life expectancy
indicating shorter survival time of patients with elevated
RDW. These results thus indicate that RDW may be
considered as a simple and easily available prognostic
factor. Such a role of RDW could be anticipated considering
that RDW may reflect the overall conditions of the patients
and be associated with their longevity (21). Further studies,

www.impactjournals.com/oncotarget

however are required to ascertain specifically molecular
mechanism(s) linking the increased RDW with poor
prognosis of CLL.

MATERIALS AND METHODS
Patients
We performed a retrospective analysis of the medical
records of a group of patients diagnosed with CLL in our
Department. Diagnosis of the disease was made on the basis
of clinical examination, morphological and immunological
criteria. The persons who had complete blood count tests
results available with the reported RDW before treatment
were enrolled into the study; those who had received a
blood transfusion within the previous six months were
excluded. Finally sixty six patients were analyzed. We used
a coding system to assure the anonymity of the patients
enrolled into the study.

Measurement of RDW
RDW was measured with use of automatic analyzer
Sysmex XS-1000i and was reported as a coefficient of
variation of the mean red blood cell volume. The reference
range for RDW was 11.5% to 14.5%.

Data collection
Firstly, the age, sex and data of CLL diagnosis were
recorded. The laboratory findings beside RDW collected
at the moment of diagnosis including white blood cell
count and lymphocyte count, hemoglobin level, platelet
count, lactate dehydrogenase level, β2microglobulin level,
presence of constitutive symptoms, lymphadenopathy or
splenomegaly were then reviewed. All patients were also
characterized according to expression of ZAP-70 and
CD 38 that were assessed with flow cytometry method
and according to presence of cytogenetic abnormalities
assessing with FISH (fluorescence in situ hybridization)
method. The next step of analysis was focused on therapy
data. We analyzed time from diagnosis to starting of the
therapy, chemotherapy regimens ordered and chemotherapy
outcome. We used the criteria of response to treatment
proposed by WG- IWCLL in 2008 [44] based on WGNCI criteria from1996 [45]. According to these criteria,
complete response requires the absence of symptoms and
organomegaly, normal complete cell counts of peripheral
blood and less than 30% of lymphocytes in bone marrow
for at least 2 months. When size of the lymph nodes, spleen
and liver, together with the peripheral blood data, were
at least 50% better than pre-treatment values, the partial
response was achieved. Other patients were considered
non-responders. As the last step of analysis time of overall
survival was analyzed.

32851
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Statistical analysis

aggressive form of chronic lymphocytic leukemia. Blood.
1999; 94:1848–1854.

The collected data were analyzed using STASTICA 12
Software by StatSoft Inc. The Mann-Whitney and Wilcoxon
tests were used for groups comparison. The Kaplan–Meier
method was employed to calculate the survival analysis.
Multivariate analysis of independent clinical factors
for survival was tested by the Cox proportional hazard
regression model. The assessment of cut-off points for
RDW were assessed by drawing of receiver operating
characteristic (ROC) curves using Medical Bundle for
STATISTICA 12. Differences were considered statistically
significant when p values were < 0.05.
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